Emtricitabine (Emtriva) vs Ulonivirine
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
HIV
Shared mechanism: HIV reverse transcriptase · full HIV pipeline
Emtricitabine (Emtriva)
Marketed by Gilead Sciences and partners
NCT00112047 · Phase 3 · completed
The trial randomized 517 participants to an active comparator, but treatment was open-label rather than double-blinded. Its hard clinical virologic endpoint was met: 84.4% versus 72.8% achieved confirmed HIV-1 RNA below 400 copies/mL at week 48 (p=0.002; 95% CI for the difference, 4.3% to 18.6%), supporting non-inferiority and a favorable result, but the lack of blinding limits the evidence strength.
Next expected readout: June 2029 · NCT07792096 (registry estimate)
Reported efficacy
Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): Percentage of Participants With Confirmed Plasma HIV-1 RNA < 400 c/mL at Week 48 (Defined by the Food and Drug Administration [FDA] Time-to-Loss-of Virologic Response [TLOVR] Algorithm (48 weeks): EFV+FTC+TDF 84.4 Percentage of participants | CBV+EFV 72.8 Percentage of participants (met)
Result source: NCT00112047
Ulonivirine
Developed by Merck & Co.
NCT04564547 · Phase 2 · completed
Randomized, triple-masked phase 2b switch study of once-weekly islatravir plus ulonivirine in virologically suppressed HIV-1 infection (161 participants). All three primary endpoints are adverse-event rates reported descriptively; no efficacy comparison was posted as primary. Its registered primary outcome on ClinicalTrials.gov is "Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind" (with 2 other safety or dose-finding measures). Its registered primary outcomes are safety, tolerability or dose-finding measures only, so the evidence grade is capped at weak.
Next expected readout: August 2027 · NCT06891066 (registry estimate)
Reported efficacy
Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind (Up to approximately 9 months); Percentage of Participants Who Discontinued Study Intervention Due to an AE During the Double-Blind Treatment Period (Up to approximately 8 months); Percentage of Participants Who Experienced One or More AEs During the Unblinded Safety Monitoring Period (Up to approximately 37 months): Percentage of Participants Who Experienced One or More Adverse Events (AEs) During the Double-Blind Treatment Period +42 Days Post-Blind (Up to approximately 9 months): Group 1: ISL 20 mg + Ulonivirine 100 mg 75 Percentage of Participants | Group 2: ISL 20 mg + Ulonivirine 200 mg 75.6 Percentage of Participants | Group 3: ISL 20 mg + Ulonivirine 400 mg 80 Percentage of Participants | Group 4: BIC/FTC/TAF 67.5 Percentage of Participants (not_applicable)
Result source: NCT04564547
Results for HIV
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Emtricitabine (Emtriva) | Ulonivirine |
|---|---|---|
| HIV-1 RNA below 50 copies/mL (week 48) | —Not posted · NCT00002416 | —Trial running · NCT07266831 |
| HIV-1 RNA 50 copies/mL or more (week 48) | —Not posted · NCT00002416 | —Trial running · NCT07266831 |
| CD4 count, change (week 48) | —Not posted · NCT00002416 | —Trial running · NCT07266831 |
HIV-1 RNA below 50 copies/mL (week 48)
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
- Ulonivirine
- —Trial running · NCT07266831
HIV-1 RNA 50 copies/mL or more (week 48)
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
- Ulonivirine
- —Trial running · NCT07266831
CD4 count, change (week 48)
- Emtricitabine (Emtriva)
- —Not posted · NCT00002416
- Ulonivirine
- —Trial running · NCT07266831
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Emtricitabine (Emtriva): 0 of 4 rows · Ulonivirine: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ulonivirine |
|---|---|
| Dropout rate | 5%400 mg weeklya NCT04564547 · Phase 2 · combination show 8 more results—400 mg weekly NCT04564547 · Phase 2 · combination —400 mg weekly NCT04564547 · Phase 2 · combination 4.9%200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination 7.5%100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination |
| Discontinued due to AEs | —400 mg weeklya NCT04564547 · Phase 2 · combination show 8 more results—400 mg weekly NCT04564547 · Phase 2 · combination —400 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination |
| Serious AEs | —400 mg weeklya NCT04564547 · Phase 2 · combination show 8 more results2.5%400 mg weekly NCT04564547 · Phase 2 · combination 2.7%400 mg weekly NCT04564547 · Phase 2 · combination —200 mg weekly NCT04564547 · Phase 2 · combination 7.3%200 mg weekly NCT04564547 · Phase 2 · combination 0%200 mg weekly NCT04564547 · Phase 2 · combination —100 mg weekly NCT04564547 · Phase 2 · combination 5%100 mg weekly NCT04564547 · Phase 2 · combination 0%100 mg weekly NCT04564547 · Phase 2 · combination |
| Most frequent reported AEs | show 5 more results |
Notes
- aPopulation comparability has not been reviewed for these studies.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Emtricitabine (Emtriva)'s landscape · Ulonivirine's landscape